Theravance's NSRI succeeds in fibromyalgia study
This article was originally published in Scrip
Executive Summary
Theravance's investigational norepinephrine and serotonin reuptake inhibitor (NSRI), TD-9855, has shown promising Phase II data in fibromyalgia, the company says, which will come as a relief following its failure in ADHD last November (scripintelligence.com, 14 November 2013).